| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/18/2002 | EP0904260B1 Inhibition of matrix metalloproteases by 2-(omega-aroylalkyl)-4-biaryl-oxobutyric acids |
| 09/18/2002 | EP0893996B1 Use of a rapamycin derivative in vasculopathies and xenotransplantation |
| 09/18/2002 | EP0874839B1 Furan- and thiophenecarbothioamide derivatives, their preparation and their use as inhibitors of the replication of hiv-1 and hiv-1 mutants |
| 09/18/2002 | EP0858461B1 Fused tropane-derivatives as neurotransmitter reuptake inhibitors |
| 09/18/2002 | EP0842267B1 Mch2, AN APOPTOTIC CYSTEINE PROTEASE, AND COMPOSITIONS FOR MAKING AND METHODS OF USING THE SAME |
| 09/18/2002 | EP0842161B1 4,5-diaryl oxazole derivatives |
| 09/18/2002 | EP0823889B1 1,3-propane diol derivatives as bioactive compounds |
| 09/18/2002 | EP0804427B1 Lta4 hydrolase inhibitors |
| 09/18/2002 | EP0772600B1 1,2-substituted imidazolyl compounds for the treatment of inflammation |
| 09/18/2002 | EP0767793B1 N-substituted-(dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines |
| 09/18/2002 | EP0700388B1 Substituted beta-aryl and beta-heteroaryl-alpha-cyanoacrylamide derivatives as tyrosine kinase inhibitors |
| 09/18/2002 | CN1370181A Effectors of dipeptidyl peptidase IV for topical use |
| 09/18/2002 | CN1370180A Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease |
| 09/18/2002 | CN1370176A Subsstituted heterocycle fused gamma-carbolines |
| 09/18/2002 | CN1370173A Isomeric fused pyrrolocarbazoles and isoindolones |
| 09/18/2002 | CN1370171A Process for preparing inhibitors of nucleoside metabolism |
| 09/18/2002 | CN1370170A DNA methyltransferase inhibitors |
| 09/18/2002 | CN1370169A Substituted heterocycle fused gamma-carbolines |
| 09/18/2002 | CN1370163A Imidazo [1,2-A] pyridine and pyrazolo [2,3-a] pyridine derivatives |
| 09/18/2002 | CN1370159A Indole derivatives and their use for treatment of osteoporosis amongst other applications |
| 09/18/2002 | CN1370158A Fatty acid synthase inhibitors |
| 09/18/2002 | CN1370156A Benzopyrans and benzothiopyrans as RAR selective retinoid agonists |
| 09/18/2002 | CN1370154A Aminothiazole derivatives and their use as CRF receptor ligands |
| 09/18/2002 | CN1370152A 5-cyano-2-aminopyrimidine derivatives |
| 09/18/2002 | CN1370146A Alpha/Beta integrin inhibitors |
| 09/18/2002 | CN1370145A Novel process |
| 09/18/2002 | CN1370082A Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| 09/18/2002 | CN1370081A Synergistic combination |
| 09/18/2002 | CN1370080A NSAID and EFGR kinase inhibitor contg. compsn. for treatment or inhibition of colonic polyps and colorectal cancer |
| 09/18/2002 | CN1370078A Prion protein peptides and uses thereof |
| 09/18/2002 | CN1370074A Method of treating malignancies and viral infections and improving immune function with dietary supplement |
| 09/18/2002 | CN1370069A Use of CGRP antagonists and CGRP release inhibitors for controlling menopausal hot flashes |
| 09/18/2002 | CN1370054A Growth promoting compsns. for mammals and method of promoting growth of mammals by using same |
| 09/18/2002 | CN1369290A 'Yizhi' capsule for brain health |
| 09/18/2002 | CN1091092C Retionic acid x-receptor ligands, its compsn. and usage |
| 09/18/2002 | CN1090916C Oral liquid for preventing altitude disease and its preparing process |
| 09/18/2002 | CA2403500A1 Substituted biphenyl derivatives |
| 09/17/2002 | US6452013 For treating conditions which are related to impairment of gastric emptying |
| 09/17/2002 | US6451994 Polypeptides, polynucleotides; drug screening; diagnosing alzheimer*s, parkinson*s, huntington*s, and creutzfelt-jacob disease; amyotrophic lateral sclerosis, cystic fibrosis |
| 09/17/2002 | US6451976 Bi-or multifunctional molecules based on a dendroaspin scaffold |
| 09/17/2002 | US6451968 Hoogsteen type base pairing in triplex motif; diagnosis; heat resistance; detection of point mutations, restriction enzyme sites, and transcription inhibition |
| 09/17/2002 | US6451853 Small molecules that elicit a polarized Th1 response and for modulation of cellular immunity |
| 09/17/2002 | US6451842 Cyclic amine derivatives and their use as drugs |
| 09/17/2002 | US6451839 Indole sPLA2 inhibitors |
| 09/17/2002 | US6451838 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 09/17/2002 | US6451836 Method of inhibiting liver glycogen phosphorylase with 2-alkylpyrrolidines |
| 09/17/2002 | US6451834 Indeno[1,2-c]-, naphtho[1,2-c]- and benzo[6,7]cyclohepta[1,2-c]pyrazole derivatives |
| 09/17/2002 | US6451829 Coumarinic compounds having IgE affecting properties |
| 09/17/2002 | US6451824 Sulfonylaminocarboxylic acids |
| 09/17/2002 | US6451819 Pyrrolidine-3-yl-sulfanyl, or sufonyl or sufinyl derivatives used in the treatment of neurodegenerative diseases |
| 09/17/2002 | US6451817 Alpha-substituted-1-benzyl-napthyls |
| 09/17/2002 | US6451812 Farnesyl protein transferase inhibitors for treating arthropathies |
| 09/17/2002 | US6451811 Herpes virus |
| 09/17/2002 | US6451810 Amide substituted imidazoquinolines |
| 09/17/2002 | US6451807 Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor |
| 09/17/2002 | US6451804 Heteroalkylamino-substituted bicyclic nitrogen heterocycles |
| 09/17/2002 | US6451803 N-acyl and n-aroyl aralkyl amides useful in treating seritonergic disorders |
| 09/17/2002 | US6451801 Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
| 09/17/2002 | US6451795 Central neurodegenerative diseases |
| 09/17/2002 | US6451791 Amidoaromatic ring sulfonamide hydroxamic acid compounds |
| 09/17/2002 | US6451789 Central nervous system disorders; cognition activators |
| 09/17/2002 | US6451786 Tyrosine kinase inhibitors |
| 09/17/2002 | US6451785 Beta lactams as antiproliferative agents |
| 09/17/2002 | US6451783 Administering to an obese patient or a patient at risk of becoming obese therapeutically effective amount of compound that attenuates binding of agouti-related protein to melanocortin receptors |
| 09/17/2002 | US6451779 Composition and method for contraception and treatment of tumors of the mammary glands |
| 09/17/2002 | US6451776 Water soluble prodrugs of hindered alcohols |
| 09/17/2002 | US6451760 Treatment of inflammation using a 2F1 polypeptide or an antibody thereto |
| 09/17/2002 | US6451595 Murine leukemia virus with pol, env, and gag coding regions deleted; gene therapy; gene expression and engineering |
| 09/17/2002 | US6451577 Human uridine disphosphate galactose-4-epimerase |
| 09/17/2002 | US6451522 Combining agent to be tested, antibody or antigen-binding fragment which binds to amino terminal domain of mammalian cc-chemokine receptor 2, mammalian cc-chemokine receptor 2 or ligand-binding variant, measuring binding |
| 09/17/2002 | US6451343 A-(methoximino)-a-(1-azabicyclo(2.2.2)oct-3-yl)acetonitrile hydrochloride amyloid precursor protein intensifier |
| 09/17/2002 | US6451318 Secreted proteins |
| 09/17/2002 | US6451310 Preventing t cell activation of b cells by administering antibody cabable of binding protein recognized by monoclonal antibody 5c8 |
| 09/17/2002 | US6451307 3′-exonuclease, production and use thereof |
| 09/17/2002 | CA2204151C Cdna encoding a bmp type ii receptor |
| 09/17/2002 | CA2057338C Diarylfluoromethane compounds |
| 09/17/2002 | CA2048096C N-benzyl-indoles |
| 09/17/2002 | CA2041832C Hydrazones |
| 09/16/2002 | CA2376844A1 Pyrazolo¢4,3-d!pyrimidin-7-ones and pyrazolo¢3,4!pyrimidin-4-ones and purinones which inhibit cgmp pdes |
| 09/16/2002 | CA2376738A1 Purine derivatives for the treatment of ischemia |
| 09/12/2002 | WO2002071064A1 Method of examining steroid-responsiveness |
| 09/12/2002 | WO2002070711A1 Vaccine |
| 09/12/2002 | WO2002070708A2 Glutamate receptor modulatory proteins and nucleic acids encoding them |
| 09/12/2002 | WO2002070669A2 Secreted proteins |
| 09/12/2002 | WO2002070655A2 Mouse cytokine receptor |
| 09/12/2002 | WO2002070654A2 Peptide deformylase inhibitors |
| 09/12/2002 | WO2002070565A2 High-affinity antagonists of elr-cxc chemokines |
| 09/12/2002 | WO2002070563A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070562A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070561A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070560A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070559A2 Nuclear hormone receptor ligand binding domains |
| 09/12/2002 | WO2002070558A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070557A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070556A1 POLYPEPTIDE OF A P53 PROTEIN-SPECIFIC MURINE Α/β T-CELL RECEPTOR, NUCLEIC ACIDS CODING THEREFOR AND USE THEREOF |
| 09/12/2002 | WO2002070555A2 Method of modulating the proliferation of medullary thyroid carcinoma cells |
| 09/12/2002 | WO2002070553A1 Tumour peptide antigen produced from human mdm2 proto-oncogene |
| 09/12/2002 | WO2002070548A2 Modified human granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity |
| 09/12/2002 | WO2002070541A2 Peptide deformylase inhibitors |
| 09/12/2002 | WO2002070540A2 Peptide deformylase inhibitors |